ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1296

Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study

Bradly Kimbrough1, Cynthia Crowson1, John Davis1, Eric Matteson2 and Elena Myasoedova1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN

Meeting: ACR Convergence 2023

Keywords: Epidemiology, interstitial lung disease, rheumatoid arthritis, Rheumatoid Factor, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Extraarticular manifestations of rheumatoid arthritis (ExRA) are associated with increased disease burden and mortality. They are also common, affecting about half of patients with RA. Two primary risk factors for developing ExRA include high disease activity and seropositivity.Given advancements in RA management in the last two decades, epidemiologic data indicating an increasing incidence of seronegative RA, and lack of recent population-based epidemiologic studies evaluating ExRA over time, it is unclear if either the frequency of ExRA or mortality associated with ExRA has changed in recent years. This study aims to assess changes in the cumulative incidence of ExRA and associated mortality risk.

Methods: Trends in ExRA occurrence were evaluated using a population-based inception cohort. All adult patients with incident RA from 1985 through 2014 meeting the 1987 American College of Rheumatology criteria were included. Patients were divided into two cohorts based on the incidence date of RA, 1985-1999 and 2000-2014. Patients were followed until the earlier of death, migration from the region, or 12/31/2000 (for patients with incident RA from 1985-1994), 12/31/2008 (for patients with incident RA from 1995-2007), or 10/15/2022 (for patients with incident RA from 2008-2014). The occurrence of ExRA was determined by manual chart review. The 10-year cumulative incidence was estimated for each ExRA in both cohorts. Cox proportional hazard models were used to determine associations between specific demographic and RA disease characteristics and ExRA and between ExRA and mortality.

Results: A total of 907 patients were included in this study. There were 296 in the 1985-1999 cohort and 611 in the 2000-2014 cohort (table 1). The earlier cohort had a median follow up of 9.5 years (interquartile range [IQR] 6.7-12.0) and the later cohort had a median follow up of 7.4 years (IQR 4-10.3 years). The 10-year cumulative incidence of any ExRA decreased significantly between the earlier and later cohorts (45.1% vs 31.6%, p< 0.001; table 2 and figure 1). This was largely driven by significant declines in subcutaneous rheumatoid nodules (30.9% vs 15.8%, p< 0.001) and non-severe ExRA (41.4% vs 28.8%, p=0.001). Several risk factors for the development of any ExRA were identified, including RF positivity (hazard ratio [HR] 2.02, 95% confidence interval [CI] 1.43-2.86), current smoking (HR 1.61, 95% CI 1.10-2.34), and erosions (HR 1.46, 95% CI 1.05-2.04). Mortality was increased in patients with either non-severe (HR 1.83, 95% CI 1.18-2.85) or severe ExRA (HR 3.05, 95% CI 1.44-6.49).

Conclusion: The incidence of ExRA has decreased over time. Despite improvements in RA therapeutics and management strategies, mortality remains increased in patients with ExRA.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: B. Kimbrough: None; C. Crowson: None; J. Davis: Girihlet, 9, Pfizer, 5, Remission Medical, 9; E. Matteson: AbbVie, 5, Alvotech Inc., 2, American College of Rheumatology, 12, Committee member, Boehringer-Ingelheim, 2, 6, Horizon Therapeutics, 1, NIH/NIAMS, 1, Practice Point Communications, 6, UpToDate, 9; E. Myasoedova: None.

To cite this abstract in AMA style:

Kimbrough B, Crowson C, Davis J, Matteson E, Myasoedova E. Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/decline-in-incidence-of-extraarticular-manifestations-of-rheumatoid-arthritis-a-population-based-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decline-in-incidence-of-extraarticular-manifestations-of-rheumatoid-arthritis-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology